Sunshine Biopharma, Inc. (SBFM)
NASDAQ: SBFM · Real-Time Price · USD
2.890
+0.040 (1.40%)
At close: Nov 4, 2024, 4:00 PM
2.929
+0.039 (1.35%)
After-hours: Nov 4, 2024, 6:33 PM EST

Company Description

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada.

It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.

The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer.

It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products.

In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications.

Sunshine Biopharma, Inc. is based in Fort Lauderdale, Florida.

Sunshine Biopharma, Inc.
Sunshine Biopharma logo
Country United States
Founded 2006
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 44
CEO Steve Slilaty

Contact Details

Address:
333 Las Olas Way, CU4 Suite 433
Fort Lauderdale, Florida 33301
United States
Phone 954-515-0810
Website sunshinebiopharma.com

Stock Details

Ticker Symbol SBFM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001402328
CUSIP Number 867781304
ISIN Number US8677814035
Employer ID 20-5566275
SIC Code 2834

Key Executives

Name Position
Dr. Steve N. Slilaty Ph.D. Chairman, President and Chief Executive Officer
Camille Sebaaly Chief Financial Officer and Secretary
Dr. Abderrazzak Merzouki Chief Science Officer and Director
Marc Beaudoin Chief Operating Officer
Malek Chamoun Chief Development Officer
Robert G. Ferreira President of Sunshine Bio Investments Inc

Latest SEC Filings

Date Type Title
Oct 23, 2024 8-K Current Report
Oct 17, 2024 DEF 14A Other definitive proxy statements
Sep 10, 2024 8-K Current Report
Aug 20, 2024 10-Q/A [Amend] Quarterly report
Aug 19, 2024 8-K Current Report
Aug 16, 2024 10-Q Quarterly Report
Aug 14, 2024 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Aug 12, 2024 8-K Current Report
Jul 11, 2024 DEF 14C Filing
Jul 2, 2024 8-K Current Report